{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-070444","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.663854+00:00","generated_at":"2026-06-14T02:48:42.368845+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aytu BioPharma prices $4M at-the-market offering, appoints new director, extends loan interest-only period","bullets":["Gross proceeds of ~$4M from 1.74M shares and pre-funded warrants at $1.84/unit; offering expected to close June 13, 2023.","Abhinav Jain of Nantahala Capital appointed to Board; Board increases from 4 to 5 members.","Company to focus on Rx segment, de-emphasize or monetize Consumer Health segment, suspend pipeline programs.","Closing of offering extends interest-only period on $15M Avenue Capital term loan through maturity in January 2025.","Common warrants (Tranche A & B) exercisable at $1.59/share for up to 4.35M shares; potential additional $7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-070444","json":"https://secwatch.observer/filing/0001104659-23-070444.json","markdown":"https://secwatch.observer/filing/0001104659-23-070444.md","text":"https://secwatch.observer/filing/0001104659-23-070444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/tm2318372d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:48:42.368845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed62fa0408","claim":"Abhinav Jain was appointed as Director at AYTU BIOPHARMA, INC.","evidence_excerpt":"Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, the size of the Board will be increased from four (4) to five (5), and Abhinav Jain shall be appointed to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c5fd3bd2745389fe12dea63e3964587d8fdaad43","claim":"AYTU BIOPHARMA, INC entered into Purchase Agreement with certain investors valued at approximately $4 million (effective 2023-06-08).","evidence_excerpt":"On June 8, 2023, Aytu BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein (the “Purchasers”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"approximately $4 million"},{"label":"Effective","value":"2023-06-08"}],"fact_type":"material_agreement"},{"claim_id":"cd5adb11b8a436bd395ed184e43718b1823566e3","claim":"AYTU BIOPHARMA, INC entered into PAA with Maxim Group LLC (effective 2023-06-08).","evidence_excerpt":"amed therein (the “Purchasers”), and a placement agency agreement (the “PAA”) with Maxim Group LLC (the “Placement Agent”), pursuant to which the Company agreed to issue and sell to investors in the offering (the","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2023-06-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}